Is Kalaris Therapeutics, Inc. Common Stock profitable?

Kalaris Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $44.1M over the trailing twelve months.

What is Kalaris Therapeutics, Inc. Common Stock's earnings per share?

Kalaris Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-2.15.

Where does Kalaris Therapeutics, Inc. Common Stock's income statement data come from?

Every line is extracted from Kalaris Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Kalaris Therapeutics, Inc. Common Stock KLRS Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Research and development	$32.3M-34.2%	$30.75M-31.7%	$27.45M—	$54.34M—	$49.11M—
General and administrative	$15.34M+47.3%	$15.4M+130%	$15.04M+8.4%	$13.25M-46.7%	$10.41M-71.4%
Other operating expenses	$47.63M-20.0%	$46.15M-10.8%	$42.48M—	$67.59M—	$59.52M—
Total operating expenses	$47.63M-20.0%	$46.15M-10.8%	$42.48M—	$67.59M—	$59.52M—
Operating income	-$47.63M+20.0%	-$46.15M+10.8%	-$42.48M+60.3%	-$67.59M+41.8%	-$59.52M+62.6%
Interest expense	$0-100%	$1.44M-46.6%	$2.75M—	$3.57M—	$4.07M—
Other income (expense), net	$3.53M+121%	$2.71M+116%	-$12.98M-876%	-$14.06M-19,633%	-$16.43M-899%
Net income	-$44.1M+41.9%	-$43.44M+37.2%	-$55.47M+48.1%	-$81.66M+27.8%	-$75.96M+50.2%
Diluted earnings per share	-$2.15+95.8%	-$4.21+91.8%	-$20.10+73.5%	-$47.62+0.9%	-$51.27-15.8%
Basic earnings per share	-$2.15+95.8%	-$4.21+91.8%	-$20.10+73.5%	-$47.62+0.9%	-$51.27-15.8%
Weighted-average shares, diluted	76.4M+847%	56.7M+965%	42.8M+403%	25.4M-79.0%	8.1M-96.2%
Weighted-average shares, basic	76.4M+847%	56.7M+965%	42.8M+403%	25.4M-79.0%	8.1M-96.2%
Change In Fair Value Of Derivative Liability	$0-100%	$1.23M-41.0%	$2.45M—	$3M—	$3.31M—
Change In Fair Value Of Tranche Liability	$0-100%	$365K-98.3%	$21.38M—	$21.38M—	$21.38M—
Loss On Extinguishment And On Issuance Of Convertible Promissory Notes	$0+100%	-$186K+99.5%	-$36.07M—	-$36.07M—	-$37.41M—
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$44.15M+42.2%	-$43.43M+55.0%	-$55.46M+58.6%	-$81.66M+41.8%	-$76.38M+57.4%
Other comprehensive income (loss)	——	——	——	——	-$1K-101%
Net unrealized gains (losses) on securities still held	——	——	——	——	-$1K-101%
Other income, net (Note 6)	$3.53M+898%	$2.75M+1,362%	$2.01M+50.4%	$1.19M-51.7%	$354K-87.9%
EBIT	-$47.63M+20.0%	-$46.15M+10.8%	-$42.48M+60.3%	-$67.59M+41.8%	-$59.52M+62.6%
EBITDA	——	——	——	——	——
EBIT	-$47.63M+20.0%	-$46.15M+10.8%	-$42.48M+60.3%	-$67.59M+41.8%	-$59.52M+62.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Kalaris Therapeutics, Inc. Common Stock profitable?: Kalaris Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $44.1M over the trailing twelve months.
What is Kalaris Therapeutics, Inc. Common Stock's earnings per share?: Kalaris Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-2.15.
Where does Kalaris Therapeutics, Inc. Common Stock's income statement data come from?: Every line is extracted from Kalaris Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.